Avoid common mistakes on your manuscript.
Erratum to: Adv Ther DOI 10.1007/s12325-013-0029-0
The authors of the above mentioned paper would like to make the following adjustment to their article. In Table 4, the column heading titled “After 60 min (n = 8)” should read “12 weeks of administration (n = 8)”. The corrected table is published here:
Table 4 Changes in hemodynamic parameters from baseline to 12 weeks after switching epoprostenol formulations
Hemodynamic parameter | Baseline (n = 8) | 12 weeks of administration (n = 8) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Actual value | Actual value | Changes from baseline | P valuea | |||||||
Mean ± SD | Median | [Min, Max] | Mean ± SD | Median | [Min, Max] | Mean ± SD | Median | [Min, Max] | ||
Systolic pulmonary artery pressure, mmHg | 50.6 ± 12.4 | 46.0 | [34, 69] | 49.8 ± 14.1 | 44.5 | [29, 70] | −0.9 ± 3.5 | −1.0 | [−5, 4] | 0.4375 |
Diastolic pulmonary artery pressure, mmHg | 17.1 ± 2.2 | 17.0 | [14, 22] | 18.8 ± 4.6 | 19.0 | [11, 24] | 1.6 ± 3.7 | 2.0 | [−3, 7] | 0.4844 |
Mean pulmonary artery pressure, mmHg | 31.1 ± 5.1 | 31.5 | [22, 40] | 31.4 ± 7.2 | 32.0 | [18, 41] | 0.3 ± 2.8 | 0.5 | [−4, 4] | 0.8906 |
Pulmonary capillary wedge pressure, mmHg | 8.4 ± 1.8 | 8.0 | [5, 11] | 7.3 ± 1.2 | 7.5 | [6, 9] | −1.1 ± 2.3 | −2.0 | [−4, 3] | 0.2344 |
Cardiac output, L/min | 4.829 ± 1.057 | 4.440 | [2.72, 5.99] | 4.499 ± 1.005 | 4.095 | [3.25, 5.98] | 0.210 ± 0.790 | 0.310 | [−0.91, 1.35] | 0.4609 |
Mean right arterial pressure, mmHg | 4.8 ± 1.8 | 4.5 | [3, 8] | 4.8 ± 1.8 | 4.5 | [3, 7] | 0.0 ± 1.7 | 0.0 | [−3, 3] | 1.0000 |
Mixed venous oxygen saturation, % | 73.43 ± 5.50 | 73.20 | [63.4, 83.2] | 72.10 ± 3.28 | 72.75 | [67.1, 76.3] | −1.33 ± 4.64 | −0.50 | [−8.4, 4.7] | 0.5469 |
Cardiac input, L/min/m2 | 2.98 ± 0.86 | 2.80 | [2.0, 4.3] | 3.11 ± 0.72 | 3.00 | [2.4, 4.3] | 0.14 ± 0.52 | −0.25 | [−0.6, 0.9] | 0.6563 |
Pulmonary vascular resistance, dyn·s/cm5 | 448.3 ± 158.1 | 429.5 | [201, 676] | 453.6 ± 175.3 | 424.5 | [154, 686] | 5.4 ± 78.3 | −25.0 | [−61, 182] | 0.5469 |
Pulmonary vascular resistance index, dyn·s/cm5/m2 | 646.5 ± 223.1 | 598.0 | [338, 1000] | 648.5 ± 239.6 | 640.5 | [251, 992] | 2.4 ± 98.4 | −15.5 | [−87, 212] | 0.7109 |
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s12325-013-0029-0.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Tamura, Y., Ono, T., Fukuda, K. et al. Erratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4). Adv Ther 30, 554–555 (2013). https://doi.org/10.1007/s12325-013-0031-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-013-0031-6